"For the first time, we found that empagliflozin, an established diabetes and heart medication, reduced markers of brain ...
Patients with Type 1 diabetes are often excluded from diabetes and weight loss trials. Forty years ago, the vast majority of patients with Type 1 diabetes didn’t need help with the problem of being ...
A comparative effectiveness study of glucose-lowering drugs finds the GLP-1 receptor agonists most protective against ...
Two researchers from Kingston University have been selected for a prestigious Innovate UK programme to help commercialise ...
The diabetes drug empagliflozin (Jardiance) and an insulin nasal spray both showed promising effects on memory, brain health ...
Californians will be able to buy five packs of insulin pens for a maximum of $55 per pack, or $11 per pen, starting Jan. 1, ...
Californians will be able to buy five packs of insulin pens for a maximum of $55 per pack, or $11 per pen, starting Jan. 1, ...
Lower-cost insulin manufactured by the state of California will be available to consumers starting Jan. 1, 2026, for about $11 per pen.
The sale of insulin is part of the state’s CalRx initiative aimed at lowering prescription drug prices for Californians.
California will begin selling affordable insulin under its own label on Jan. 1, nearly three years after it first announced a partnership to sell state-branded generic drugs at lower prices.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback